Physician profile
Fouad J Moawad
NPI 1447221007
$725,248.63
in general payments reported to CMS, 2019-2025
29 companies · $206K in 2025
The $206K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $3,549 · 2021: $14K · 2022: $89K · 2023: $220K · 2024: $192K · 2025: $206K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $502K · Travel and Lodging: $88K · Consulting Fee: $16K · Food and Beverage: $12K · Education: $18.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $502,382.00 |
| Travel and Lodging | $87,685.28 |
| Consulting Fee | $15,679.00 |
| Food and Beverage | $11,793.80 |
| Education | $18.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $307,074.73 | 2022-2025 | Dupixent |
| Genzyme Corporation | $266,907.99 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $93,357.70 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31,719.94 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $13,173.59 | 2023-2025 | Voquezna |
| Regeneron Pharmaceuticals, INC. | $5,310.15 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $2,264.45 | 2022 | |
| Abbvie INC. | $1,637.67 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,215.18 | 2019-2025 | Xifaxan |
| Allergan, INC. | $1,028.07 | 2019-2020 | |
| Janssen Biotech, INC. | $387.39 | 2021-2025 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $274.15 | 2019-2024 | Dificid, Zinplava, Recarbrio |
| Ferring Pharmaceuticals INC. | $213.61 | 2019-2025 | Rebyota |
| Qol Medical, LLC | $114.63 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $108.35 | 2023-2025 | Vowst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $76.30 | 2021-2024 | Talicia |
| Ardelyx, INC. | $63.60 | 2024 | Ibsrela |
| Celgene Corporation | $61.62 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $49.13 | 2022-2023 | Sutab |
| Celltrion USA INC. | $33.99 | 2024-2025 | Zymfentra, Vegzelma |
| Pfizer INC. | $29.86 | 2025 | |
| Phadia US INC. | $26.58 | 2021-2025 | Immunocap |
| Novo Nordisk INC | $23.16 | 2025 | Wegovy |
| Shire North American Group INC | $21.03 | 2019 | |
| Laborie Medical Technologies Corp. | $18.48 | 2024 | Alphaone |
| Pinnacle Biologics, INC | $15.87 | 2022 | |
| W. L. Gore & Associates, INC. | $14.91 | 2020 | |
| Intercept Pharmaceuticals, INC. | $14.71 | 2024 | |
| Vivus LLC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fouad Moawad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.